Ameriprise
ABCL icon

Ameriprise’s AbCellera Biologics ABCL Stock Holding History

Ameriprise’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-289,836
Closed -$858K – 3924
2024
Q2 		$858K Hold
289,836
– – ﹤0.01% 3214
2024
Q1 		$1.31M Sell
289,836
-50
-0% -$255 ﹤0.01% 3058
2023
Q4 		$1.66M Sell
289,886
-3,684
-1% -$17.1K ﹤0.01% 2966
2023
Q3 		$1.35M Buy
293,570
+341
+0.1% +$2.07K ﹤0.01% 3010
2023
Q2 		$1.89M Buy
293,229
+2,101
+0.7% +$14.3K ﹤0.01% 2899
2023
Q1 		$2.2M Buy
291,128
+47,846
+20% +$434K ﹤0.01% 2804
2022
Q4 		$2.46M Buy
+243,282
New +$2.81M ﹤0.01% 2714
2021
Q2 		– Sell
-524,690
Closed -$17.8M – 3881
2021
Q1 		$17.8M Buy
524,690
+216,547
+70% +$8.63M 0.01% 1407
2020
Q4 		$12.4M Buy
+308,143
New +$14.1M ﹤0.01% 1580

Other funds holding ABCL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
VOYA Investment Management
VOYA Investment Management Atlanta, Georgia $116B AUM 61.47% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Ameriprise's ABCL Position: Q3 2024 in Review

Ameriprise sold out of AbCellera Biologics (ABCL) in Q3 2024, closing a stake of 289,836 shares — an estimated $858K sold.

Ameriprise first reported a position in ABCL in Q4 2020 and held it in 9 quarters. The position peaked at $17.8M in Q1 2021. 139 funds tracked by Wall St. Rank hold ABCL as of Q3 2024.

  • Ameriprise reported no remaining AbCellera Biologics position as of Q3 2024 after selling out during the quarter.
  • Ameriprise sold 289,836 AbCellera Biologics shares in Q3 2024, an estimated $858K.
  • Ameriprise first reported a position in AbCellera Biologics in Q4 2020 and held it in 9 quarters.
  • Ameriprise's AbCellera Biologics position peaked at $17.8M in Q1 2021.
  • 139 funds tracked by Wall St. Rank held AbCellera Biologics as of Q3 2024.

Based on Ameriprise's 13F filing for Q3 2024, filed 14 Nov 2024.